Sign in or create an account to add this stock to your watchlist.
About Alder BioPharmaceuticals (NASDAQ:ALDR)
Alder BioPharmaceuticals, Inc. operates as a clinical-stage biopharmaceutical company. It discovers, develops, and commercializes therapeutic antibodies to transform the treatment paradigm for patients with migraine and other serious neurological or inflammatory conditions in the United States, Australia, and Ireland. The company's lead pivotal-stage product candidate, Eptinezumab, a monoclonal antibody inhibiting calcitonin gene-related peptide, which is in Phase III pivotal trials for the prevention of migraine. Its product candidate pipeline also includes ALD1910, a preclinical monoclonal antibody that targets pituitary adenylate cyclase-activating polypeptide-38; and Clazakizumab, that has completed two Phase 2b clinical trials designed to block the pro-inflammatory cytokine IL-6. Alder BioPharmaceuticals, Inc. was incorporated in 2002 and is headquartered in Bothell, Washington.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:ALDR
CUSIPN/A
Phone425-205-2900
Debt
Debt-to-Equity Ratio0.57
Current Ratio13.31
Quick Ratio13.30
Price-To-Earnings
Trailing P/E Ratio-3.05
Forward P/E Ratio-3.08
P/E GrowthN/A
Sales & Book Value
Annual Sales$1.62 million
Price / Sales632.43
Cash FlowN/A
Price / CashN/A
Book Value$4.12 per share
Price / Book3.67
Profitability
EPS (Most Recent Fiscal Year)($4.95)
Net Income$-288,870,000.00
Net MarginsN/A
Return on Equity-97.70%
Return on Assets-72.39%
Miscellaneous
Employees193
Outstanding Shares67,850,000
Alder BioPharmaceuticals (NASDAQ:ALDR) Frequently Asked Questions
What is Alder BioPharmaceuticals' stock symbol?
Alder BioPharmaceuticals trades on the NASDAQ under the ticker symbol "ALDR."
How were Alder BioPharmaceuticals' earnings last quarter?
Alder BioPharmaceuticals (NASDAQ:ALDR) issued its quarterly earnings results on Tuesday, May, 8th. The biopharmaceutical company reported ($1.73) earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of ($1.23) by $0.50. View Alder BioPharmaceuticals' Earnings History.
What price target have analysts set for ALDR?
12 brokerages have issued twelve-month price objectives for Alder BioPharmaceuticals' stock. Their predictions range from $11.00 to $51.00. On average, they expect Alder BioPharmaceuticals' stock price to reach $27.9167 in the next twelve months. View Analyst Ratings for Alder BioPharmaceuticals.
What are Wall Street analysts saying about Alder BioPharmaceuticals stock?
Here are some recent quotes from research analysts about Alder BioPharmaceuticals stock:
- 1. Needham & Company LLC analysts commented, "Alder had a busy 1Q with new CEO, CMO, and COO hires. After a thorough internal review, the team now expects Epti BLA submission to be completed in 1Q19 (was 2H18). Importantly, all gating CMC and clinical activities for BLA filing remain on track. As such, we moved our estimated epti launch from 4Q19 to 1Q20. We don’t expect the slight delay to market to significantly impact overall uptake. Epti’s differentiated profile (rapid onset, deep magnitude of effect) was highlighted at the AAN conference in April. We believe epti is sufficiently differentiated from competitors and think it can capture ~15% of the CGRP migraine prevention market (~$1.1B peak U.S. sales). Maintain BUY." (5/9/2018)
- 2. Canaccord Genuity analysts commented, "We eagerly await a potential update on a filing timeline for ALDR’s eptinezumab ALDR will hold its 1Q18 call after the market closes on Tuesday, 5/8. In our view, investors are most focused on a potential update on the filing timeline for ALDR’s eptinezumab (for migraine prevention). Recall that when ALDR appointed an interim CEO, the accompanying press release did not reiterate the original expectation for a 2H18 filing (see here). As the anti-CGRP mechanism of action in migraine prevention has been validated several times over not only by ALDR, but also by other competitors in the space (Amgen/Novartis, Lilly and Teva), we acknowledge there is some risk around why the company did not reiterate its filing timeline. We are hopeful that the business update on ALDR’s 1Q18 call could help resolve some of this uncertainty." (5/9/2018)
- 3. According to Zacks Investment Research, "Alder Biopharmaceuticals Inc. is a clinical-stage biopharmaceutical company. It discovers, develops and seeks to commercialize therapeutic antibodies. It is developing monoclonal antibodies comprising ALD403, for the prevention of migraine; and Clazakizumab, in the treatment of rheumatoid arthritis and psoriatic arthritis. Alder Biopharmaceuticals Inc. is headquartered in Bothell, Washington. " (5/1/2018)
- 4. Mizuho analysts commented, "We spoke with the company a couple of times late last week and this week after the announcement that CEO Randall Schatzman was stepping down. Our view on eptinezumab having a competitive and differentiated profile in the crowded migraine space has not changed. While the CEO transition brings uncertainties, it may help position the company as a commercial organization sooner. In our view, the best way to unlock the value of eptinezumab is through an acquisition by a larger company with substantial U.S. commercial experience. We recommend buying the shares on weakness." (3/28/2018)
Who are some of Alder BioPharmaceuticals' key competitors?
Some companies that are related to Alder BioPharmaceuticals include Blueprint Medicines (BPMC), Array Biopharma (ARRY), Ultragenyx Pharmaceutical (RARE), Amicus Therapeutics (FOLD), Supernus Pharmaceuticals (SUPN), Ascendis Pharma (ASND), Ironwood Pharmaceuticals (IRWD), Portola Pharmaceuticals (PTLA), Clovis Oncology (CLVS), Tesaro (TSRO), Emergent BioSolutions (EBS), Horizon Pharma (HZNP), Global Blood Therapeutics (GBT), The Medicines (MDCO) and Heron Therapeutics (HRTX).
Who are Alder BioPharmaceuticals' key executives?
Alder BioPharmaceuticals' management team includes the folowing people:
- Mr. Paul B. Cleveland, Interim Pres, CEO & Director (Age 61)
- Dr. John A. Latham, Co-Founder, Chief Scientific Officer & Head of R&D (Age 58)
- Mr. Larry K. Benedict, Principal Accounting Officer and Exec. VP (Age 57)
- Ms. Elisabeth A. Sandoval, Chief Commercial Officer & Exec. VP of Corp. Strategy (Age 56)
- Dr. Timothy M. Whitaker, Consultant (Age 59)
Has Alder BioPharmaceuticals been receiving favorable news coverage?
News headlines about ALDR stock have been trending somewhat positive on Tuesday, according to Accern Sentiment. The research group identifies negative and positive media coverage by monitoring more than twenty million blog and news sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Alder BioPharmaceuticals earned a daily sentiment score of 0.02 on Accern's scale. They also gave news articles about the biopharmaceutical company an impact score of 46.52 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the company's share price in the immediate future.
Who are Alder BioPharmaceuticals' major shareholders?
Alder BioPharmaceuticals' stock is owned by many different of retail and institutional investors. Top institutional investors include
REDMILE GROUP, LLC
(9.99%), REDMILE GROUP, LLC (9.99%), NB PUBLIC EQUITY K (5.00%), Foresite Capital Management III LLC (4.34%), Palo Alto Investors LP (2.73%) and Foresite Capital Management II LLC (2.49%). Company insiders that own Alder BioPharmaceuticals stock include Jeffrey T L Smith, John A Latham, Mark James Litton, Randall C Schatzman and Stephen M Dow. View Institutional Ownership Trends for Alder BioPharmaceuticals.
Which institutional investors are selling Alder BioPharmaceuticals stock?
ALDR stock was sold by a variety of institutional investors in the last quarter, including Citigroup Inc., Pinnacle Associates Ltd., Millennium Management LLC, Virginia Retirement Systems ET AL, Baird Financial Group Inc., Schwab Charles Investment Management Inc., Teacher Retirement System of Texas and California State Teachers Retirement System. Company insiders that have sold Alder BioPharmaceuticals company stock in the last year include Jeffrey T L Smith and Mark James Litton. View Insider Buying and Selling for Alder BioPharmaceuticals.
Which institutional investors are buying Alder BioPharmaceuticals stock?
ALDR stock was acquired by a variety of institutional investors in the last quarter, including Bellevue Group AG, Foresite Capital Management II LLC, Massachusetts Financial Services Co. MA, Dimensional Fund Advisors LP, UBS Group AG, Foresite Capital Management III LLC, Candriam Luxembourg S.C.A. and Tiverton Asset Management LLC. View Insider Buying and Selling for Alder BioPharmaceuticals.
How do I buy shares of Alder BioPharmaceuticals?
Shares of ALDR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Alder BioPharmaceuticals' stock price today?
One share of ALDR stock can currently be purchased for approximately $15.10.
How big of a company is Alder BioPharmaceuticals?
Alder BioPharmaceuticals has a market capitalization of $1.03 billion and generates $1.62 million in revenue each year. The biopharmaceutical company earns $-288,870,000.00 in net income (profit) each year or ($4.95) on an earnings per share basis. Alder BioPharmaceuticals employs 193 workers across the globe.
How can I contact Alder BioPharmaceuticals?
Alder BioPharmaceuticals' mailing address is 11804 NORTH CREEK PARKWAY SOUTH, BOTHELL WA, 98011. The biopharmaceutical company can be reached via phone at 425-205-2900 or via email at [email protected]
MarketBeat Community Rating for Alder BioPharmaceuticals (ALDR)
MarketBeat's community ratings are surveys of what our community members think about Alder BioPharmaceuticals and other stocks. Vote "Outperform" if you believe ALDR will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ALDR will underperform the S&P 500 over the long term. You may vote once every thirty days.
Alder BioPharmaceuticals (NASDAQ:ALDR) Price Target and Consensus Rating
(How are Consensus Ratings Calculated?) MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
12 Wall Street analysts have issued ratings and price targets for Alder BioPharmaceuticals in the last 12 months. Their average twelve-month price target is $27.9167, suggesting that the stock has a possible upside of 84.88%. The high price target for ALDR is $51.00 and the low price target for ALDR is $11.00. There are currently 2 hold ratings and 10 buy ratings for the stock, resulting in a consensus rating of "Buy."
| Today | 30 Days Ago | 90 Days Ago | 180 Days Ago |
| Consensus Rating: | Buy | Buy | Buy | Buy |
| Consensus Rating Score: | 2.83 | 2.75 | 2.77 | 2.77 |
| Ratings Breakdown: | 0 Sell Rating(s)
2 Hold Rating(s)
10 Buy Rating(s)
0 Strong Buy Rating(s) | 1 Sell Rating(s)
1 Hold Rating(s)
10 Buy Rating(s)
0 Strong Buy Rating(s) | 1 Sell Rating(s)
1 Hold Rating(s)
11 Buy Rating(s)
0 Strong Buy Rating(s) | 1 Sell Rating(s)
1 Hold Rating(s)
11 Buy Rating(s)
0 Strong Buy Rating(s) |
| Consensus Price Target: | $27.9167 | $28.1667 | $29.0769 | $29.2308 |
| Price Target Upside: | 84.88% upside | 144.93% upside | 104.77% upside | 141.08% upside |
Alder BioPharmaceuticals (NASDAQ:ALDR) Consensus Price Target History
Alder BioPharmaceuticals (NASDAQ:ALDR) Analyst Ratings History
Show:
(Data available from 5/22/2016 forward)
Alder BioPharmaceuticals (NASDAQ:ALDR) Dividend History by Quarter
| Announced | Period | Amount | Yield | Ex-Dividend Date | Record Date | Payable Date |
|---|
(Data available from 1/1/2013 forward)
Alder BioPharmaceuticals (NASDAQ ALDR) Insider Trading and Institutional Ownership History
Insider Ownership Percentage: 10.60%
Alder BioPharmaceuticals (NASDAQ ALDR) Insider Trading History
| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
|---|
| 5/16/2018 | Jeffrey T L Smith | Insider | Sell | 12,161 | $15.03 | $182,779.83 | 5,871 |  |
| 11/13/2017 | Mark James Litton | Insider | Sell | 16,519 | $10.80 | $178,405.20 | 116,451 | |
| 10/16/2017 | Mark James Litton | Insider | Sell | 16,520 | $12.33 | $203,691.60 | 116,452 | |
| 7/18/2017 | Stephen M Dow | Director | Buy | 25,000 | $10.00 | $250,000.00 | | |
| 6/20/2017 | Jeffrey T L Smith | VP | Sell | 585 | $20.00 | $11,700.00 | 1,416 | |
| 1/18/2017 | Mark James Litton | Insider | Sell | 1,498 | $23.10 | $34,603.80 | 101,430 | |
| 1/9/2017 | Mark James Litton | Insider | Sell | 9,516 | $23.01 | $218,963.16 | | |
| 12/1/2016 | Jeffrey T. L. Smith | VP | Sell | 3,000 | $22.78 | $68,340.00 | | |
| 12/1/2016 | John A. Latham | Insider | Sell | 3,636 | $22.78 | $82,828.08 | | |
| 11/7/2016 | Randall C Schatzman | CEO | Sell | 10,000 | $25.16 | $251,600.00 | 124,768 | |
| 10/17/2016 | Mark James Litton | Insider | Sell | 6,000 | $27.50 | $165,000.00 | 99,567 | |
| 10/3/2016 | Jeffrey T L Smith | VP | Sell | 3,000 | $31.14 | $93,420.00 | 3,000 | |
| 10/3/2016 | John A Latham | Insider | Sell | 10,000 | $31.32 | $313,200.00 | 252,200 | |
| 10/3/2016 | Randall C Schatzman | CEO | Sell | 8,181 | $31.15 | $254,838.15 | 122,949 | |
| 9/1/2016 | Jeffrey T L Smith | VP | Sell | 3,000 | $32.49 | $97,470.00 | 3,000 | |
| 9/1/2016 | Randall C Schatzman | Insider | Sell | 10,000 | $32.48 | $324,800.00 | 124,768 | |
| 8/15/2016 | Jeffrey T L Smith | VP | Sell | 3,000 | $31.17 | $93,510.00 | 3,000 | |
| 8/1/2016 | John A Latham | Insider | Sell | 10,000 | $31.19 | $311,900.00 | 252,200 | |
| 7/27/2016 | John A Latham | Insider | Sell | 10,000 | $30.14 | $301,400.00 | 243,013 | |
| 7/25/2016 | Randall C Schatzman | Insider | Sell | 10,000 | $28.08 | $280,800.00 | 124,768 | |
| 6/13/2016 | Mark James Litton | Insider | Sell | 6,000 | $28.94 | $173,640.00 | 74,567 | |
| 6/3/2016 | Jeffrey T L Smith | VP | Sell | 16,090 | $30.20 | $485,918.00 | 16,090 | |
| 6/1/2016 | John A Latham | Insider | Sell | 10,000 | $30.02 | $300,200.00 | 252,200 | |
| 5/31/2016 | Mark James Litton | Insider | Sell | 25,000 | $30.05 | $751,250.00 | 79,847 | |
| 5/27/2016 | John A Latham | Insider | Sell | 6,401 | $30.05 | $192,350.05 | 248,601 | |
| 5/24/2016 | Randall C Schatzman | CEO | Sell | 10,000 | $28.02 | $280,200.00 | 115,933 | |
| 4/18/2016 | Randall C Schatzman | CEO | Sell | 30,000 | $28.07 | $842,100.00 | 124,409 | |
| 1/4/2016 | Mark James Litton | insider | Sell | 25,000 | $31.40 | $785,000.00 | 73,718 | |
| 1/4/2016 | Randall C. Schatzman | CEO | Sell | 10,000 | $31.47 | $314,700.00 | 111,579 | |
| 12/1/2015 | Jeffrey T. L. Smith | VP | Sell | 4,272 | $37.24 | $159,089.28 | | |
| 12/1/2015 | John A. Latham | insider | Sell | 4,550 | $37.24 | $169,442.00 | 241,726 | |
| 12/1/2015 | Randall C. Schatzman | CEO | Sell | 10,000 | $37.24 | $372,400.00 | 111,579 | |
| 11/30/2015 | Stephen M Dow | Director | Sell | 88 | $37.11 | $3,265.68 | | |
| 11/2/2015 | Jeffrey T. L. Smith | VP | Sell | 3,900 | $33.67 | $131,313.00 | | |
| 11/2/2015 | John A. Latham | insider | Sell | 4,545 | $33.69 | $153,121.05 | 241,265 | |
| 11/2/2015 | Randall C. Schatzman | CEO | Sell | 10,000 | $33.71 | $337,100.00 | 109,921 | |
| 10/1/2015 | Jeffrey T. L. Smith | VP | Sell | 3,900 | $32.25 | $125,775.00 | | |
| 10/1/2015 | John A. Latham | insider | Sell | 4,545 | $32.26 | $146,621.70 | 241,265 | |
| 9/1/2015 | Jeffrey T. L. Smith | VP | Sell | 3,900 | $38.50 | $150,150.00 | | |
| 9/1/2015 | John A. Latham | insider | Sell | 4,545 | $38.52 | $175,073.40 | 209,447 | |
| 8/31/2015 | Stephen M Dow | Director | Sell | 16,218 | $38.75 | $628,447.50 | | |
| 6/12/2015 | Larry Benedict | VP | Sell | 25,454 | $47.46 | $1,208,046.84 | | |
| 6/4/2015 | John A Latham | Insider | Sell | 25,000 | $44.18 | $1,104,500.00 | | |
| 6/1/2015 | Jeffrey T L Smith | VP | Sell | 3,900 | $41.53 | $161,967.00 | | |
| 6/1/2015 | John A Latham | Insider | Sell | 4,545 | $41.53 | $188,753.85 | | |
| 5/22/2015 | Jeffrey T L Smith | VP | Sell | 61,818 | $38.86 | $2,402,247.48 | | |
| 5/21/2015 | Stephen M Dow | Director | Sell | 20,000 | $65.69 | $1,313,800.00 | | |
| 5/20/2015 | Stephen M Dow | Director | Sell | 8,462 | $40.39 | $341,780.18 | | |
| 5/18/2015 | Clay B Siegall | Director | Sell | 38,181 | $37.62 | $1,436,369.22 | | |
| 4/1/2015 | Jeffrey T L Smith | VP | Sell | 3,900 | $27.43 | $106,977.00 | | |
| 4/1/2015 | John A Latham | Insider | Sell | 19,045 | $29.54 | $562,589.30 | | |
| 3/30/2015 | John A Latham | Insider | Sell | 14,500 | $30.20 | $437,900.00 | | |
| 1/27/2015 | Jeffrey T L Smith | VP | Sell | 3,900 | $28.01 | $109,239.00 | | |
| 1/27/2015 | John A Latham | Insider | Sell | 15,045 | $28.33 | $426,224.85 | | |
| 1/27/2015 | Randall C Schatzman | CEO | Sell | 100,000 | $28.42 | $2,842,000.00 | | |
| 1/26/2015 | Jeffrey T L Smith | VP | Sell | 2,700 | $27.89 | $75,303.00 | | |
| 1/26/2015 | Mark James Litton | Insider | Sell | 5,200 | $28.03 | $145,756.00 | | |
| 1/26/2015 | Randall C Schatzman | CEO | Sell | 36,422 | $27.93 | $1,017,266.46 | | |
| 11/24/2014 | Jeffrey T L Smith | VP | Sell | 29,090 | $16.08 | $467,767.20 | | |
| 5/13/2014 | A/S Novo | Insider | Buy | 550,000 | $10.00 | $5,500,000.00 | | |
| 5/13/2014 | Alan Bruce Montgomery | Director | Buy | 3,000 | $10.00 | $30,000.00 | | |
| 5/13/2014 | West 8 Limited Partne Ventures | Major Shareholder | Buy | 250,000 | $10.00 | $2,500,000.00 | | |
(Data available from 1/1/2013 forward)
Alder BioPharmaceuticals (NASDAQ ALDR) News Headlines
| Source: |
|
| Date | Headline |
|---|
 | Canaccord Genuity Reiterates $20.00 Price Target for Alder BioPharmaceuticals (ALDR)
www.americanbankingnews.com - May 21 at 6:28 PM |
 | Migraine Space in Focus as AMGN/NVS' Aimovig Gets FDA Nod
finance.yahoo.com - May 21 at 5:09 PM |
| Alder BioPharmaceuticals (ALDR) Expected to Post Earnings of -$1.16 Per Share
www.americanbankingnews.com - May 20 at 1:27 PM |
| Alder BioPharmaceuticals (ALDR) Insider Jeffrey T. L. Smith Sells 12,161 Shares
www.americanbankingnews.com - May 18 at 8:19 PM |
 | Research Report Identifies Armstrong World Industries, Empire State Realty Trust, Alder BioPharmaceuticals, Cadence ...
www.nasdaq.com - May 17 at 6:34 PM |
| Alder BioPharmaceuticals (ALDR) Stock Rating Upgraded by BidaskClub
www.americanbankingnews.com - May 17 at 5:51 PM |
| Research Report Identifies Armstrong World Industries, Empire State Realty Trust, Alder BioPharmaceuticals, Cadence, World Wrestling Entertainment, and Cato with Renewed Outlook — Fundamental Analysis, Calculating Forward Movement
finance.yahoo.com - May 17 at 8:24 AM |
| Leerink Swann Comments on Alder BioPharmaceuticals' Q2 2018 Earnings (ALDR)
www.americanbankingnews.com - May 11 at 9:30 AM |
| Alder BioPharmaceuticals (ALDR) Receives Average Recommendation of "Buy" from Analysts
www.americanbankingnews.com - May 10 at 3:35 PM |
| Alder BioPharmaceuticals (ALDR) Upgraded at ValuEngine
www.americanbankingnews.com - May 10 at 12:48 PM |
| Edited Transcript of ALDR earnings conference call or presentation 8-May-18 9:00pm GMT
finance.yahoo.com - May 10 at 8:26 AM |
| Alder BioPharmaceuticals (ALDR) Rating Reiterated by Needham & Company LLC
www.americanbankingnews.com - May 9 at 9:42 PM |
| Alder BioPharmaceuticals (ALDR) Earns Buy Rating from Canaccord Genuity
www.americanbankingnews.com - May 9 at 9:42 PM |
| Alder BioPharmaceuticals (ALDR) PT Set at $21.00 by BMO Capital Markets
www.americanbankingnews.com - May 9 at 6:39 PM |
| Alder BioPharmaceuticals (ALDR) Releases Quarterly Earnings Results, Misses Expectations By $0.50 EPS
www.americanbankingnews.com - May 9 at 1:43 PM |
 | Alder Biopharmaceuticals' (ALDR) CEO Paul Cleveland on Q1 2018 Results - Earnings Call Transcript
seekingalpha.com - May 9 at 8:20 AM |
| Alder BioPharmaceuticals: 1Q Earnings Snapshot
finance.yahoo.com - May 8 at 5:38 PM |
| Alder BioPharmaceuticals® Reports First Quarter 2018 Financial and Operating Results
finance.yahoo.com - May 8 at 5:38 PM |
| Alder Biopharmaceuticals Inc’s (NASDAQ:ALDR) Shift From Loss To Profit
finance.yahoo.com - May 8 at 5:38 PM |
| Alder Biopharmaceuticals, Inc. (ALDR)
finance.yahoo.com - May 8 at 8:18 AM |
| Alder BioPharmaceuticals® to Present at the 2018 Bank of America Merrill Lynch Health Care Conference
finance.yahoo.com - May 7 at 5:37 PM |
| -$1.26 Earnings Per Share Expected for Alder BioPharmaceuticals (ALDR) This Quarter
www.americanbankingnews.com - May 3 at 3:08 AM |
| Alder BioPharmaceuticals (ALDR) Scheduled to Post Quarterly Earnings on Tuesday
www.americanbankingnews.com - May 2 at 8:47 PM |
| Alder BioPharmaceuticals (ALDR) Downgraded by Zacks Investment Research to Sell
www.americanbankingnews.com - May 1 at 6:06 PM |
| Alder BioPharmaceuticals® to Host Conference Call to Discuss First Quarter 2018 Financial and Operating Results
finance.yahoo.com - April 30 at 5:13 PM |
| Alder BioPharmaceuticals® Appoints Jeremy Green to its Board of Directors
finance.yahoo.com - April 26 at 5:16 PM |
 | Alder BioPharma (ALDR) Presents 12-Month Data of Eptinezumab in PROMISE 1 Phase 3 Trial Showing Long-Term Reduction in Episodic Migraine
www.streetinsider.com - April 25 at 5:28 PM |
| Alder BioPharma (ALDR) Says New Data Demonstrated Eptinezumab Increased Migraine-Free Intervals and Improved Quality-of-Life Outcomes
www.streetinsider.com - April 25 at 5:28 PM |
 | Alder BioPharmaceuticals® New Data Demonstrated Eptinezumab Increased Migraine ...
globenewswire.com - April 25 at 5:28 PM |
| Alder BioPharmaceuticals® New Data Demonstrated Eptinezumab Increased Migraine-Free Intervals (Up to 32.5 days) and Improved Quality-of-Life Outcomes in Patients with Episodic Migraine
finance.yahoo.com - April 25 at 5:28 PM |
| Alder's eptinezumab shows treatment benefit in late-stage migraine study
seekingalpha.com - April 25 at 8:21 AM |
| Your Daily Pharma Scoop: Alder's Migraine Data, Centene Revenues, Tesaro's Positive Results
seekingalpha.com - April 25 at 8:21 AM |
 | Benzinga's Top Upgrades, Downgrades For April 24, 2018
www.benzinga.com - April 24 at 5:34 PM |
| Alder BioPharmaceuticals® Appoints Eric Carter, Ph.D., MD, as Interim Chief Medical Officer
globenewswire.com - April 24 at 5:34 PM |
 | BRIEF-Alder Biopharmaceuticals Presents New 12-Month Data Of Eptinezumab In Promise 1 Phase 3 Trial
www.reuters.com - April 24 at 5:34 PM |
| Alder BioPharmaceuticals® Presents New 12-Month Data of Eptinezumab in PROMISE 1 Phase 3 Trial Showing Long ...
globenewswire.com - April 24 at 5:34 PM |
| Goldman Sachs Neutral On Alder Biopharma As Launch Of Migraine Treatment Approaches
finance.yahoo.com - April 24 at 5:34 PM |
| Alder BioPharmaceuticals (ALDR) Downgraded by BidaskClub
www.americanbankingnews.com - April 24 at 11:02 AM |
| Goldman Sachs Begins Coverage on Alder BioPharmaceuticals (ALDR)
www.americanbankingnews.com - April 24 at 8:58 AM |
| Alder BioPharmaceuticals® Appoints Eric Carter, Ph.D., M.D., as Interim Chief Medical Officer
finance.yahoo.com - April 23 at 5:13 PM |
| Alder BioPharmaceuticals poaches Amgen vet for new chief operating officer role
finance.yahoo.com - April 23 at 5:13 PM |
| Alder BioPharmaceuticals (ALDR) Raised to Sell at ValuEngine
www.americanbankingnews.com - April 20 at 7:28 PM |
| BRIEF-Alder Biopharmaceuticals Inc To Present New Phase 3 Migraine Prevention Data For Eptinezumab
www.reuters.com - April 20 at 8:25 AM |
| Alder BioPharmaceuticals® to Present New Phase 3 Migraine Prevention Data for ...
globenewswire.com - April 18 at 5:44 PM |
| Alder BioPharmaceuticals® to Present New Phase 3 Migraine Prevention Data for Eptinezumab at the 70th Annual American Academy of Neurology Meeting
finance.yahoo.com - April 18 at 5:44 PM |
| Needham & Company LLC Analysts Give Alder BioPharmaceuticals (ALDR) a $36.00 Price Target
www.americanbankingnews.com - April 17 at 10:21 PM |
| Alder BioPharmaceuticals® Appoints Erin Lavelle to Newly Created Role of Chief Operating Officer
finance.yahoo.com - April 16 at 5:24 PM |
| Alder BioPharmaceuticals (ALDR) Expected to Post Earnings of -$1.26 Per Share
www.americanbankingnews.com - April 16 at 1:25 AM |
| Alder BioPharmaceuticals (ALDR) Receives Consensus Rating of "Buy" from Brokerages
www.americanbankingnews.com - April 15 at 3:35 PM |
| Alder BioPharmaceuticals (ALDR) Raised to Buy at BidaskClub
www.americanbankingnews.com - April 14 at 7:21 AM |
Alder BioPharmaceuticals (NASDAQ:ALDR) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Alder BioPharmaceuticals (NASDAQ:ALDR) Income Statement, Balance Sheet and Cash Flow Statement
Alder BioPharmaceuticals (NASDAQ ALDR) Stock Chart for Tuesday, May, 22, 2018
Loading chart…
